Department of Medicine, Division of Infectious Diseases and Immunology
Immunology of Infectious Disease | Immunopathology
The inflammasome NLRP3 is activated by pathogen associated molecular patterns (PAMPs) during infection, including RNA and proteins from influenza A virus (IAV). However, chronic activation by danger associated molecular patterns (DAMPs) can be deleterious to the host. We show that blocking NLRP3 activation can be either protective or detrimental at different stages of lethal influenza A virus (IAV). Administration of the specific NLRP3 inhibitor MCC950 to mice from one day following IAV challenge resulted in hypersusceptibility to lethality. In contrast, delaying treatment with MCC950 until the height of disease (a more likely clinical scenario) significantly protected mice from severe and highly virulent IAV-induced disease. These findings identify for the first time that NLRP3 plays a detrimental role later in infection, contributing to IAV pathogenesis through increased cytokine production and lung cellular infiltrates. These studies also provide the first evidence identifying NLRP3 inhibition as a novel therapeutic target to reduce IAV disease severity.
Rights and Permissions
Copyright © 2016, The Author(s).
DOI of Published Version
Sci Rep. 2016 Jun 10;6:27912. doi: 10.1038/srep27912. Link to article on publisher's site
Tate MD, Ong JD, Dowling JK, McAuley JL, Robertson AB, Latz E, Drummond GR, Cooper MA, Hertzog PJ, Mansell A. (2016). Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. Open Access Articles. https://doi.org/10.1038/srep27912. Retrieved from https://escholarship.umassmed.edu/oapubs/2810
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.